Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | CNR1 | P21554 | 9/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3561349 | 0.89 | KDM4E (0.55) | KDM4EKMT2ACNR1 | |
| SCHEMBL13804337 | 0.86 | — | — | |
| SCHEMBL14433838 | 0.85 | KDM4E (0.59) | KDM4EKMT2A | |
| SCHEMBL28790391 | 0.82 | KDM4E (0.50) | KDM4EKMT2AOPRM1CYP1A2 | |
| SCHEMBL24946123 | 0.80 | KDM4E (0.38) | KDM4EKMT2ACNR1CNR2CYP1A2 | |
| SCHEMBL3554211 | 0.80 | KMT2A (0.42) | KDM4EKMT2ACNR1 | |
| Hydrochloric Acid SCHEMBL10500403 | 0.79 | KDM4E (0.47) | KDM4EKMT2AOPRM1 | |
| SCHEMBL27643339 | 0.79 | KDM4E (0.43) | KDM4EKMT2AOPRM1 | |
| SCHEMBL5395425 | 0.79 | KDM4E (0.43) | KDM4EKMT2ACNR1 | |
| Hydrochloric Acid SCHEMBL4837442 | 0.78 | KDM4E (0.41) | KDM4EKMT2ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618987-A1 | METHODS FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE BY MODULATING OR INHIBITING CANNABINOID RECEPTOR 1 | Joyboy The Igwe L.L.C. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2024129891-A1 | METHODS FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE BY MODULATING OR INHIBITING CANNABINOID RECEPTOR 1 | JOYBOY THE IGWE L.L.C. (US) | 2024-06-20 | — | — | WO | claimed |
| CN-101583593-A | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof | PFIZER PROD INC (US) | 2009-11-18 | — | — | CN | claimed |
| CN-122036731-A | CB1 receptor inverse agonist compound, pharmaceutical composition, preparation method and application thereof | 北京康辰药业股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20250333418-A1 | PURINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NOVO NORDISK AS (DK) | 2025-10-30 | — | — | US | disclosed |
| EP-4618987-A1 | METHODS FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE BY MODULATING OR INHIBITING CANNABINOID RECEPTOR 1 | Joyboy The Igwe L.L.C. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4608835-A1 | PURINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Novo Nordisk A/S (DK) | 2025-09-03 | — | — | EP | disclosed |
| CN-120129684-A | Purine compound, composition containing same and use thereof | 诺和诺德股份有限公司 | 2025-06-10 | — | — | CN | disclosed |
| US-20250145628-A1 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NOVO NORDISK A/S (DK) | 2025-05-08 | — | — | US | disclosed |
| CN-119301126-A | Pyrazolopyrimidine compound, composition containing pyrazolopyrimidine compound and application of pyrazolopyrimidine compound | 诺和诺德股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| EP-4479402-A1 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Novo Nordisk A/S (DK) | 2024-12-25 | — | — | EP | disclosed |
| US-20040157838-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| US-20040092520-A1 | Purine compounds and uses thereof | PFIZER INC. | 2004-05-13 | — | — | US | disclosed |
| WO-2004037823-A1 | PURINE COMPOUNDS AND USES THEREOF AS CANNABINOID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| EP-1268454-A1 | SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074796-A1 | SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-10-11 | — | — | WO | disclosed |
| EP-0808303-A1 | 5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1997-11-26 | — | — | EP | disclosed |
| WO-1996024582-A1 | 5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1996-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157838-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | KDM4E 3361/4885KMT2A 3816/4885CNR1 1/4885 |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | KDM4E 3361/4885KMT2A 3816/4885CNR1 1/4885 |
| US-20250145628-A1 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | CNR1, CNR2, TRPV1 | KDM4E 2777/4885KMT2A 3336/4885CNR1 1/4885 |
| US-20250333418-A1 | PURINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | CNR1, CNR2, P2RY1 | KDM4E 3616/4885KMT2A 3780/4885CNR1 1/4885 |
| US-20040092520-A1 | Purine compounds and uses thereof | CNR1, CNR2, P2RY1 | KDM4E 3634/4885KMT2A 3941/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.